Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
208.04
-8.06 (-3.73%)
Feb 27, 2026, 4:00 PM EST - Market closed
Natera Employees
Natera had 6,140 employees as of December 31, 2025. The number of employees increased by 1,706 or 38.48% compared to the previous year.
Employees
6,140
Change (1Y)
1,706
Growth (1Y)
38.48%
Revenue / Employee
$375,588
Profits / Employee
-$33,902
Market Cap
29.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,140 | 1,706 | 38.48% |
| Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
| Dec 31, 2023 | 3,293 | 275 | 9.11% |
| Dec 31, 2022 | 3,018 | 348 | 13.03% |
| Dec 31, 2021 | 2,670 | 855 | 47.11% |
| Dec 31, 2020 | 1,815 | 776 | 74.69% |
| Dec 31, 2019 | 1,039 | 64 | 6.56% |
| Dec 31, 2018 | 975 | 82 | 9.18% |
| Dec 31, 2017 | 893 | 41 | 4.81% |
| Dec 31, 2016 | 852 | 136 | 18.99% |
| Dec 31, 2015 | 716 | 42 | 6.23% |
| Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| Mettler-Toledo International | 18,100 |
| Agilent Technologies | 18,100 |
| IDEXX Laboratories | 11,000 |
| Illumina | 10,080 |
| Waters | 7,900 |
NTRA News
- 2 days ago - Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation - Business Wire
- 3 days ago - Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors - Seeking Alpha
- 3 days ago - Natera Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 5 days ago - Alger SICAV - Alger Dynamic Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 6 days ago - Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer - Business Wire
- 10 days ago - Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions - Seeking Alpha
- 12 days ago - Alger Mid Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha